Last update 21 Nov 2024
HLX-35
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), EGFR modulators(Epidermal growth factor receptor erbB1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with HLX-35A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 (Recombinant Humanized Anti-EGFR and Anti-4-1BB Bispecific Antibody Injection) in Combination With HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Patients With Advanced or Metastatic Solid Tumors
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of HLX35 (Recombinant Human Anti-EGFR and Anti-4-1BB Bispecific Antibody) in Patients With Advanced or Metastatic Solid Tumors
一项评估HLX35（重组人源抗EGFR与抗4-1BB双特异性抗体）在晚期或转移性实体瘤患者中的安全性、耐受性、药代动力学特征及初步疗效的Ⅰ期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of HLX35 (recombinant human anti-EGFR and anti-4-1BB bispecific antibody) in patients with advanced or metastatic solid tumors
100 Clinical Results associated with HLX-35
Login to view more data
100 Translational Medicine associated with HLX-35
Login to view more data
100 Patents (Medical) associated with HLX-35
Login to view more data
100 Deals associated with HLX-35
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Phase 2 | CN | 30 Jan 2023 | |
| Metastatic Solid Tumor | Phase 1 | CN | 03 Jun 2022 | |
| Squamous non-small cell lung cancer | Phase 1 | CN | 03 Jun 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | AU | 08 Feb 2022 | |
| Refractory Malignant Solid Neoplasm | Phase 1 | AU | 08 Feb 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free